FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules

FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules

Background: Pancreatic adenocarcinoma is the fourth leading cause of cancer-related death. In cases with metastasis, the combination of 5-fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX) or gemcitabine-based chemotherapy regimens are considered the standard of care. However, the optimal sequen...

Full description

Bibliographic Details
Main Authors:	Francesca Foschini, Fabiana Napolitano, Alberto Servetto, Roberta Marciano, Eleonora Mozzillo, Anna Chiara Carratù, Antonio Santaniello, Pietro De Placido, Priscilla Cascetta, Giovanni Butturini, Isabella Frigerio, Paolo Regi, Nicola Silvestris, Sabina Delcuratolo, Enrico Vasile, Caterina Vivaldi, Cataldo Bianco, Sabino De Placido, Luigi Formisano, Roberto Bianco
Format:	Article
Language:	English
Published:	SAGE Publishing 2020-09-01
Series:	Therapeutic Advances in Medical Oncology
Online Access:	https://doi.org/10.1177/1758835920947970

Similar Items

Neoadjuvant Treatment in Locally Advanced Pancreatic Cancer (LAPC) Patients with FOLFIRINOX or Gemcitabine NabPaclitaxel: A Single-Center Experience and a Literature Review
by: Fabiana Napolitano, et al.
Published: (2019-07-01)

Use of FOLFIRINOX or Nab-Paclitaxel Plus Gemcitabine for the Treatment of Locally Advanced Pancreatic Adenocarcinoma: A Single Institution Observational Study
by: Alberto Servetto, et al.
Published: (2021-09-01)

Tumour Microenvironment and Immune Evasion in EGFR Addicted NSCLC: Hurdles and Possibilities
by: Antonio Santaniello, et al.
Published: (2019-09-01)

Activity and Safety of NAB-FOLFIRI and NAB-FOLFOX as First-Line Treatment for metastatic Pancreatic Cancer (NabucCO Study)
by: Elisa Giommoni, et al.
Published: (2021-05-01)

Sustained Improvement in a Metastatic Colon Cancer Patient with FOLFIRI-Aflibercept after FOLFOX Failure
by: Shyam Aggarwal
Published: (2015-11-01)

Delayed response to maintenance therapy after first-line chemotherapy in metastatic intrahepatic cholangiocarcinoma: a case report
by: Roberta Marciano, et al.
Published: (2017-09-01)

Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study
by: Portales Fabienne, et al.
Published: (2009-09-01)

Equivalent Efficacy but Different Safety Profiles of Gemcitabine Plus Nab-Paclitaxel and FOLFIRINOX in Metastatic Pancreatic Cancer
by: Ilario Giovanni Rapposelli, et al.
Published: (2021-05-01)

FOLFOXIRI versus FOLFOX or FOLFIRI with targeted therapy in patients with mutant BRAF metastatic colorectal cancer: A systematic review and meta-analysis
by: M. Yu. Fedyanin, et al.
Published: (2020-12-01)

Phase I study of high-dose ascorbic acid with mFOLFOX6 or FOLFIRI in patients with metastatic colorectal cancer or gastric cancer
by: Feng Wang, et al.
Published: (2019-05-01)

Impact of Sarcopenia on Patients with Localized Pancreatic Ductal Adenocarcinoma Receiving FOLFIRINOX or Gemcitabine as Adjuvant Chemotherapy
by: Victor Mortier, et al.
Published: (2022-12-01)

Induction Chemotherapy With FOLFIRINOX Followed by Chemoradiation With Gemcitabine in Patients With Borderline-Resectable Pancreatic Ductal Adenocarcinoma
by: Ana Acuna-Villaorduna MD, et al.
Published: (2022-10-01)

Systematic review and meta-analysis of gemcitabine-based chemotherapy after FOLFIRINOX in advanced pancreatic cancer
by: Victor H. F. de Jesus, et al.
Published: (2020-02-01)

FOLFIRI-bevacizumab as a second-line treatment for advanced biliary tract cancer after gemcitabine-based chemotherapy
by: Nicolas Roussot, et al.
Published: (2023-11-01)

Gemcitabine/Nab-Paclitaxel versus FOLFIRINOX in Locally Advanced Pancreatic Cancer: A European Multicenter Study
by: Nicolas Williet, et al.
Published: (2021-06-01)

Attenuated FOLFIRINOX in the salvage treatment of gemcitabine-refractory advanced pancreatic cancer: a phase II study
by: Jung Hoon Kim, et al.
Published: (2018-06-01)

Time to Definitive Health-Related Quality of Life Score Deterioration in Patients with Resectable Metastatic Colorectal Cancer Treated with FOLFOX4 versus Sequential Dose-Dense FOLFOX7 followed by FOLFIRI: The MIROX Randomized Phase III Trial.
by: Zeinab Hamidou, et al.
Published: (2016-01-01)

Randomized Phase 2 Study Comparing Pathological Responses of Resected Colorectal Cancer Metastases after Bevacizumab with mFOLFOX6 or FOLFIRI (BEV-ONCO Trial)
by: Pamela Baldin, et al.
Published: (2022-02-01)

Optimizing First-Line Chemotherapy in Metastatic Pancreatic Cancer: Efficacy of FOLFIRINOX versus Nab-Paclitaxel Plus Gemcitabine
by: Francesco Di Costanzo, et al.
Published: (2023-01-01)

Prognosticators for Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Therapy and Pancreatectomy
by: Yi Tat Tong, et al.
Published: (2023-05-01)

Computational modeling of pancreatic cancer patients receiving FOLFIRINOX and gemcitabine-based therapies identifies optimum intervention strategies.
by: Kimiyo N Yamamoto, et al.
Published: (2019-01-01)

First line modified Folfirinox versus gemcitabine for advanced pancreatic cancer: A single institution retrospective experience
by: Emrah Eraslan, et al.
Published: (2019-04-01)

Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter?
by: Ursula M. Vogl, et al.
Published: (2019-01-01)

Resection of Locally Advanced Pancreatic Neoplasms after Neoadjuvant Chemotherapy with Nab-Paclitaxel and Gemcitabine following FOLFIRINOX Failure
by: Sarah Hahn, et al.
Published: (2017-08-01)

Baseline serum uric acid level is associated with progression-free survival, disease control rate, and safety in postoperative patients with colorectal cancer treated by FOLFOX, FOLFIRI, or XELOX
by: Xi Zhang, et al.
Published: (2022-07-01)

Comparative effectiveness and resource utilization of nab-paclitaxel plus gemcitabine vs FOLFIRINOX or gemcitabine for the first-line treatment of metastatic pancreatic adenocarcinoma in a US community setting
by: Braiteh F, et al.
Published: (2017-04-01)

Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancer
by: Masaru Fukahori, et al.
Published: (2023-11-01)

Modified FOLFIRINOX compared to Gemcitabine & nab-Paclitaxel in advanced pancreatic ductal adenocarcinoma - results of a match-pair analysis
by: Anant Ramaswamy, et al.
Published: (2023-01-01)

Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer
by: Masashi Sawada, et al.
Published: (2020-05-01)

Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine FOLFIRINOX in advanced pancreatic cancer: a systematic review
by: Elena Gabriela Chiorean, et al.
Published: (2019-05-01)

Cost‐effectiveness of neoadjuvant FOLFIRINOX versus gemcitabine plus nab‐paclitaxel in borderline resectable/locally advanced pancreatic cancer patients
by: Myles A. Ingram, et al.
Published: (2022-09-01)

Intensified Neoadjuvant Chemotherapy with Nab-Paclitaxel plus Gemcitabine Followed by FOLFIRINOX in a Patient with Locally Advanced Unresectable Pancreatic Cancer
by: Volker Kunzmann, et al.
Published: (2014-09-01)

Corrigendum to Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine FOLFIRINOX in advanced pancreatic cancer: a systematic review
Published: (2019-08-01)

Folfirinox gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score study
by: Nicolas Williet, et al.
Published: (2019-09-01)

Treatment Outcomes and Prognostic Factors of Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy after Modified FOLFIRINOX in Unresectable Pancreatic Cancer
by: Takafumi Mie, et al.
Published: (2023-01-01)

Meta-analysis and indirect treatment comparison of modified FOLFIRINOX and gemcitabine plus nab-paclitaxel as first-line chemotherapy in advanced pancreatic cancer
by: Jiayuan Chen, et al.
Published: (2021-07-01)

C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel
by: Tsuyoshi Shirakawa, et al.
Published: (2023-05-01)

Comparative Effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the First-Line Setting of Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis
by: Sara Pusceddu, et al.
Published: (2019-04-01)

The efficacy and safety of Nab-paclitaxel plus gemcitabine versus mFOLFIRINOX in the first-line treatment of metastatic pancreatic cancer: a retrospective study
by: Lei Yang, et al.
Published: (2023-01-01)

Efficacy and safety of FOLFIRINOX as second-line chemotherapy for advanced pancreatic cancer after gemcitabine-based therapy: A systematic review and meta-analysis
by: Wenjie Lu, et al.
Published: (2022-04-01)